Posted on January 23rd, 2012 by
The experimental cancer drug regorafenib appears to extend survival slightly in patients with metastatic colorectal cancer, a new trial indicates…"The drug was tested on patients with metastatic colorectal cancer who had progressed after standard therapies, meaning they had no treatment options available," lead researcher Dr. Axel Grothey, a professor of oncology at the Mayo Clinic, said during a noon press conference at the Gastrointestinal Cancers Symposium in San Francisco on Tuesday. Additional coverage: MSN Health, LA Times, Medical News Today, San Francisco Chronicle
HealthDay, by Steven Reinberg, 1/17/2012
You must be logged-in to the site to post a comment.